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Objective: This study aimed to determine the rates of different fetal chromosomal abnormalities among
women of advanced maternal age in China and to discuss the possible misdiagnosis risks of newer
molecular techniques, for selection of appropriate prenatal screening and diagnostic technologies.
Materials and Methods: Second trimester amniocentesis and fetal karyotype results of 46,258 women
were retrospectively reviewed. All women were  35 years old with singleton pregnancies. The rates of
clinically signiﬁcant chromosomal abnormalities (CSCAs), incidence of chromosomal abnormalities, and
correlations with age were determined.
Results: From 2001 to 2010, the proportion of women of advanced maternal age undergoing prenatal
diagnosis increased from 20% to 46%. The mean age was 37.4 years (range, 35e46 years). A total of 708
cases of CSCAs, with a rate of 1.53% were found. Trisomy 21 was the most common single chromosome
abnormality and accounted for 55.9% of all CSCAs with an incidence of 0.86%. Trisomy 13, trisomy 18,
and trisomy 21, the most common chromosome autosomal aneuploidies, accounted for 73.6% of all
CSCAs, with a rate of 1.13%. As a group, the most common chromosomal aneuploidies (13/18/21/X/Y)
accounted for 93.9% of all abnormalities, with a rate of 1.44%. The incidence of trisomy 21, trisomy 13/
18/21 as a group, and 13/18/21/X/Y as a group was signiﬁcantly greater in women aged 39 years and
older (p < 0.001), but was not different between women aged 35 years, 36 years, 37 years, and
38 years.
Conclusion: These ﬁndings may assist in genetic counseling of advanced maternal age pregnant women,
and provide a basis for the selection of prenatal screening and diagnostic technologies.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).l of Medicine, Zhejiang Uni-
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Advanced maternal age (AMA) is an important risk factor for
fetal chromosomal abnormalities [1]. Since the 1970s, amniocen-
tesis and fetal karyotype analysis have generally been performed
during the second trimester for AMA women [2]. In China, this
strategy has been implemented for more than 10 years and has
improved the detection rate of fetal chromosomal abnormality [3].
However, the population of China is over 1.3 billion, and in early
2014 the Chinese government launched its second-child policy,
allowing some couples to have a second child [4]. This is expected
to increase the number of AMA women as well as the demand for
prenatal diagnoses. Owing to the associated risk of birth defects,
AMA women are generally advised to undergo prenatal diagnosis
directly in China, receiving fetal chromosomal analysis without
necessarily undergoing prenatal screening.
Meanwhile, cytogenetic technical resources for prenatal diag-
nosis of fetal chromosomal abnormalities are already recognized as
being insufﬁcient, creating a bottleneck in prenatal diagnosis in
China [5,6]. This shortage of resources for prenatal karyotype
analysis will be exacerbated even further by the increased numbers
of AMAwomen and increased demand for prenatal diagnoses. Birth
defects and genetic diseases in China are increasing [3,5]. Therefore,
in China, it has become critical to improve methods of prenatal
diagnosis to help reduce the incidence of birth defects.
While karyotype analysis is accurate and reliable and is
considered the gold standard for prenatal diagnosis of chromo-
somal abnormalities, it is technically demanding and labor
intensive, and has a low throughput and long detection cycle
(2e3 weeks). Newer rapid and effective molecular techniques
may be alternatives to karyotype analysis for prenatal testing and
diagnosis, including noninvasive prenatal testing (NIPT), quanti-
tative ﬂuorescent polymerase chain reaction (QF-PCR), ﬂuores-
cence in situ hybridization (FISH), BACs-on-Beads (BoBs),
multiplex ligation-dependent probe ampliﬁcation (MLPA), chro-
mosomal microarray analysis (CMA), and other technologies
[7e11]. Some of these methods are able to reach a sensitivity of
98% or more with low false-positive rates [7e11]. However, risk
may still exist. Although a newer molecular method (such as QF-
PCR) provides accurate and reproducible results when compared
with karyotype analysis, it only detects common trisomies, leav-
ing a residual risk for a pregnancy to have a chromosomal ab-
normality detectable with conventional analysis methods [7,12].
The residual risk is reported to be 1%, which raises concerns as
well as ethical issues [4]. Residual risk has not been conﬁrmed in a
mainland Chinese population or validated among AMA women in
China.
Considering the increased demand for prenatal diagnosis and
the current status of prenatal testing, an urgent need emerges for
newer methods to assist in karyotype testing for prenatal diagnosis
in China. Understanding the incidence of chromosomal abnor-
malities by age would provide a good basis for developing appro-
priate techniques and strategies for prenatal screening and
diagnosis [7,13,14]. However, a few large-sample epidemiological
studies of prenatal diagnostic strategies have been performed for
AMA women in China [4]. We hypothesized that a large, multi-
center, epidemiologic study of AMA women across China would
help determine the incidence of clinically signiﬁcant chromosomal
abnormalities (CSCAs) in pregnant women referred for karyotype
analysis solely because of AMA. Therefore, this study aimed to
determine the rates of fetal chromosomal abnormalities in AMA
women in China and also to evaluate the possible misdiagnosis
risks of newer molecular techniques in clinical prenatal diagnosis.
Results of this study may assist in genetic counseling of AMA
pregnant women, and provide a basis for the selection ofappropriate prenatal screening and diagnostic technologies to
augment present methods.
Methods
Participants
Data of 46,258 pregnant women who sought counseling
because of AMA from January 2001 to December 2010 at 13 pre-
natal diagnosis centers in China were collected and analyzed
retrospectively. Only patients with a naturally conceived, singleton
pregnancy, with no personal or family history of chromosomal
abnormalities and no fetal abnormalities detected by ultrasound or
other indications of an unfavorable prenatal diagnosis, were
included. Women with any family history of chromosomal abnor-
malities and any fetal abnormalities detected by ultrasound or
other indications of an unfavorable prenatal diagnosis were
excluded. The medical centers were informed of the inclusion and
exclusion criteria, and the different centers individually compiled
the data and forwarded it to the primary center for analysis. This
study was approved by the Scientiﬁc Research Ethics Committee of
Women's Hospital of Zhejiang University, Hangzhou, China and the
Institutional Review Boards of the participating centers, and all
patients provided informed consent.
Counseling and genetic testing
All 46,258 women received genetic counseling, and then inva-
sive prenatal diagnosis was performed after informed consent was
obtained. Amniocentesis and karyotype analysis of amniotic ﬂuid
were performed at 18e22þ6 weeks of gestation. The women's ages
at due date, results of the karyotype analysis, gestational age of
pregnancy at the time of amniocentesis, and other pertinent in-
formation were sent to the Prenatal Diagnosis Center of Zhejiang
Province for analysis.
Chromosome abnormalities were divided into two categories:
chromosomal abnormalities of clear clinical signiﬁcance (CSCAs)
and chromosomal abnormalities with a good or unclear prognosis.
In this study, CSCAs included both common and rare abnormalities.
Common chromosomal abnormalities included ﬁve common types
of abnormalities affecting the number of chromosomes (13, 18, 21,
X, and Y): autosomal aneuploidies (trisomy 21, trisomy 18, and
trisomy 13), sex chromosome abnormalities (e.g., Turner syndrome,
47,XXY), polyploidies, and chimeras based on the type of involved
chromosomal abnormality. Rare chromosomal abnormalities
included imbalanced chromosomal structural abnormalities
attributable to the addition or deletion of genetic material, such as
partial chromosomal deletions or duplications.
The womenwere divided into seven groups based on their ages
at their due dates: 35 years, 36 years, 37 years, 38 years, 39 years,
and 40 years, and older than 40 years. The incidences of trisomy 21
and other CSCAs were calculated. Chromosomal abnormalities with
a good or unclear prognosis, including balanced translocations,
Robertsonian translocations, inversions, other balanced chromo-
some structural abnormalities, andmarker chromosomes, were not
analyzed in the present study. To examine the suitability of diag-
nostic techniques other than karyotype analysis, CSCAs were
divided into three categories: (1) common autosomal aneuploidies,
including trisomy 21, trisomy 18, and trisomy 13, which can be
detected with NIPT, QF-PCR, FISH, and other techniques, as previ-
ously described [7,15]; (2) common chromosomal abnormalities
involving ﬁve chromosomes (13, 18, 21, X, and Y), including trisomy
21, trisomy 18, trisomy 13, Turner syndrome, 47,XXX, 47,XXY,
47,XYY, 69,XXY, and 69,XYY, which can be detected using QF-PCR,
FISH, BoBs, MLPA, CMA, and other technologies [7e9,15]; and (3)
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letions and additions, and unbalanced translocations, which can be
detected by CMA [9,16].
Statistical analysis
A Chi-square test was performed for comparison of the in-
cidences of chromosomal abnormalities between groups. Pearson's
correlation was used to analyze the correlations between the in-
cidences of chromosomal abnormalities and age. A p value < 0.05
was considered statistically signiﬁcant. SPSS version 16 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis.
Results
A total of 46,258 singleton pregnancies were included in the
analysis; the details of the cases collected from the centers are
shown in Table S1. The mean maternal age at the due date was
37.4 years (range, 35e46 years). From 2001 to 2010, the proportion
of AMA women undergoing prenatal diagnosis increased from 20%
to 46% (Figure 1). Among the 46,258 women, there were 708 cases
of CSCAs (Table 1). The incidence of trisomy 21 was 0.86% (396/
46,258), accounting for 55.9% of all CSCAs, and the incidence tended
to increase with maternal age (Figure 2). The incidence of trisomy
21 did not differ in women aged 35 years, 36 years, 37 years, and
38 years (p¼ 0.10), and themean incidence of trisomy 21was 0.65%
(224/34,287). The mean incidence of trisomy 21 in women aged
39 years and older was 1.44% (172/11,971), which was signiﬁcantly
different from that of the 35e38-year age group (p < 0.001)
(Table 2). The incidences of trisomy 18, 47,XXX, and 47,XXY were
signiﬁcantly correlated with maternal age (g ¼ 0.77, p ¼ 0.042;
g ¼ 0.93, p ¼ 0.002; and g ¼ 0.85, p ¼ 0.014, respectively). The
incidences of trisomy 13, Turner syndrome, and 47,XYY were not
found to be signiﬁcantly correlated with maternal age.
The overall incidence of CSCAs was 1.53% (708/46,258), and
showed a tendency to increase with age (Figure 3). The combina-
tion of trisomies 13, 18, and 21 (T21/18/13 group), with a detection
rate of 1.13% (521/46,258), accounted for 73.6% (521/708) of all
CSCAs. The common chromosomal abnormalities of ﬁve chromo-
somes (13, 18, 21, X, and Y; 21/18/13/X/Y group), with a detection
rate of 1.44% (665/46,258), accounted for 93.9% (665/708) of all
CSCAs. Rare chromosomal abnormalities, including partial chro-
mosome imbalance and unbalanced translocations, with a detec-
tion rate of 0.09% (43/46,258), accounted for 6.1% (43/708) of all
CSCAs. There were no signiﬁcant differences in the incidence of theFigure 1. Change in the relative number of pregnancies in which mothers were older
than 35 years, during 2001e2010.T21/18/13 and 21/18/13/X/Y groups among women aged 35 years,
36 years, 37 years, and 38 years (p > 0.05). However, the incidence
of the T21/18/13 and 21/18/13/X/Y groups in women aged 39 years,
40 years, and older than 40 years was signiﬁcantly different from
that in the 35e38-year age group (p < 0.001). The incidence of rare
chromosomal abnormalities did not increase with age, and their
relative proportion of CSCAs tended to decrease with age (Table 3).
Discussion
Results of the present large-scale epidemiologic study of AMA
pregnant women in China who underwent second trimester
amniocentesis and fetal karyotyping showed that the need for fetal
karyotype testing has increased from 20% to 46% over the past
decade. The ﬁve most common types of chromosomal abnormal-
ities (21/18/13/X/Y group) accounted for 93.9% of all CSCAs, with
trisomy 21 accounting for over half of these. The incidence of tri-
somy 21 was similar between women aged 35e38 years, but
increased signiﬁcantly in those aged 39 years and older. Prior to the
present study, no detailed informationwas available on the relative
incidence of speciﬁc chromosomal anomalies in AMA pregnancies
in China. Results of this largemulticenter investigation suggest that
alternatives to karyotype analysis are applicable in China and can
help meet the increased demand for prenatal diagnoses among an
increasing population of AMAwomen. This work complements the
large national effort to reduce the incidence of birth defects, and
results may contribute to the development of national policies on
prenatal diagnosis.
The proportion of AMA women undergoing prenatal diagnostic
testing in China is increasing along with the demand for prenatal
diagnosis. This trend is consistent with the increases noted in
Western countries [17e20]. In China, the “second-child policy” is
placing an additional burden on already overburdened cytogenetic
technical resources. Thus, rapid, noninvasive, and cost-effective
diagnostic techniques are needed urgently, and data on the fre-
quency of chromosomal abnormalities with respect tomaternal age
should help determine which alternatives to karyotype analysis are
suitable.
Incidence of speciﬁc chromosomal abnormalities
In the present study, the overall incidence of CSCAs was 1.53%,
which is lower than that reported in previous studies, including
2.31% in Taiwan [21], 2.4% in Spain [13], and 4.3% in Turkey [22]. The
reason for this lower number may be that the current study
included only abnormalities with clear clinical signiﬁcance. The
discrepancy may also be related to the age distribution of the
participants since the frequency of some CSCAs is directly associ-
ated with maternal age [23].
In China, the incidence of trisomy 21 among AMAwomen in the
second trimester was 0.86%, accounting for over half of all CSCAs.
This highlights the importance of prenatal diagnosis of Down
syndrome for older pregnant women, especially because it is sub-
stantially higher than the 0.125% reported for the general popula-
tion of pregnant women [24]. The incidence of trisomy 21 was also
found to increase with maternal age; however, there were differ-
ences from other reports [23,24]. The current study showed a
similar incidence between women aged 35e38 years, while it
increased signiﬁcantly in those aged 39 years and older. Results of
the present study also showed that the incidences of trisomy 18,
47,XXX, and 47,XXY correlated closely with maternal age, but cor-
relations were not seen with trisomy 13, Turner syndrome, and
47,XYY, which is also consistent with other reports [23,24].
Results of the present study suggest that different strategies
may be used in pregnant women 35e38 years of age and in those
Table 1
Clinically signiﬁcant chromosomal abnormalities by age group.
Age (y) No. of cases Trisomy 21 Trisomy 18a Trisomy 13b Turner syndromeb 47,XXXc 47,XXYd 47,XYYb Other abnormalitiese
35 9946 77 (0.77) 13 (0.13) 5 (0.05) 13 (0.13) 3 (0.03) 8 (0.08) 2 (0.02) 9 (0.09)
36 9923 51 (0.51) 12 (0.12) 4 (0.04) 10 (0.10) 5 (0.05) 7 (0.07) 1 (0.01) 10 (0.10)
37 8012 58 (0.72) 17 (0.21) 1 (0.01) 8 (0.10) 4 (0.05) 9 (0.11) 1 (0.01) 8 (0.10)
38 6406 38 (0.59) 20 (0.31) 3 (0.05) 5 (0.08) 4 (0.06) 8 (0.12) 0 7 (0.11)
39 4459 39 (0.87) 14 (0.31) 1 (0.02) 3 (0.07) 5 (0.11) 9 (0.20) 1 (0.02) 5 (0.11)
40 3276 36 (1.10) 19 (0.58) 2 (0.06) 3 (0.09) 3 (0.09) 10 (0.31) 4 (0.12) 2 (0.06)
>40 4236 97 (2.29) 13 (0.31) 1 (0.02) 2 (0.05) 5 (0.12) 9 (0.21) 2 (0.05) 2 (0.05)
Total 46,258 396 (0.86) 108 (0.23) 17 (0.04) 44 (0.10) 29 (0.06) 60 (0.13) 11 (0.02) 43 (0.09)
Data are presented as n (%), unless otherwise indicated.
a The incidence of trisomy 18 was signiﬁcantly associated with maternal age (R ¼ 0.77, p ¼ 0.042).
b The incidences of trisomy 13, Turner syndrome, and 47,XYY were not associated with maternal age (p > 0.05).
c The incidence of 47,XXX was signiﬁcantly associated with maternal age (R ¼ 0.93, p ¼ 0.002).
d The incidence of 47,XXY was signiﬁcantly associated with maternal age (R ¼ 0.85, p ¼ 0.014).
e Other chromosomal abnormalities of clinical signiﬁcance includes abnormalities with imbalanced genetic material and poor prognosis other than the ﬁve common types
of chromosomal aneuploidy (13, 18, 21, X, and Y), such as partial chromosome deletions and additions, and unbalanced translocations.
Figure 2. Relationship between the incidence of trisomy 21 during the second
trimester and maternal age. Figure 3. Relationship between the incidence of clinically signiﬁcant chromosomal
abnormalities and maternal age.
Y. Zhu et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 379e384382who are older. Unlike in previous reports [23,24], in this study, the
incidence of trisomy 21was not found to increase signiﬁcantly with
age within a range of 35e38 years. However, in women aged
39 years and older, the incidence of trisomy 21, and that of other
CSCAs, increased signiﬁcantly with age. The difference with other
reports may be due to population differences. In the present
study, the 35e38-year-old age groups accounted for 74.12% of all
women, but the incidence of Down syndrome was 0.65%, signiﬁ-
cantly lower than the 1.44% in the 25% of women aged 39 years and
older. Based on the fact that the detection rate of the current pre-
natal screening technology can exceed 90% [25], American
Congress of Obstetricians and Gynecologists (ACOG) guidelines
recommend routine prenatal screening for older pregnant women
[2]. Based on the results of the present study and the ACOG
guidelines, prospective studies on prenatal screening for AMA
pregnant women 35e38 years of age should be conducted to
determine whether these methods can be viable alternatives to
karyotype analysis in this age group.Table 2
Incidence of trisomy 21 in women 35e38 years of age and those 39 years of age.
Age group (y) No. of cases Trisomy 21 cases
35e38 34,287 224
39 11,971 172
*A signiﬁcant difference was observed in the incidence of trisomy 21 between the groupNew technologies as alternatives to karyotype analysis
The current analysis indicates that the most common chromo-
somal anomalies in China can be detected using newer prenatal
screening technologies, including the analysis of free fetal DNA in
peripheral blood (NIPT), QF-PCR, CMA, and other technologies that
have matured and offer high sensitivities and low false-negative
rates [7e11,13,15,26]. The detection rates of the three most com-
mon chromosomal abnormalities, trisomy 21, trisomy 18, and tri-
somy 13, using NIPT are above 98%, with a false-positive rate under
0.5% [27]. Based on these values, ACOG has included AMA as an
indication for noninvasive DNA testing [15]. However, the accuracy
of detecting chromosomal abnormalities other than trisomy 21,
trisomy 18, and trisomy 13 is not as high. In the present study, for
example, NIPT would have detected 73.6% of CSCAs, but may have
missed 20.3% of sex chromosome abnormalities and 6.1% of otherIncidence of trisomy 21 (%)* Positive predictive value
0.65 1:154
1.44 1:69
s (p < 0.001).
Table 3
Incidence of three types of chromosomal abnormalities by age group.
Age group (y) Rate of all abnormalities Rate of three autosomal aneuploidiesa
(out of all abnormalities)
Rate of ﬁve common chromosome aneuploidiesb
(out of all abnormalities)
Rate of rare abnormalitiesc
(out of all abnormalities)
35 1.30 0.95 (73.1) 1.21 (93.1) 0.09 (6.9)
36 1.01 0.68 (67.0) 0.91 (90.0) 0.10 (10.0)
37 1.32 0.95 (71.7) 1.22 (92.5) 0.10 (7.5)
38 1.33 0.95 (71.8) 1.22 (91.8) 0.11 (8.2)
39 1.73 1.21 (70.1) 1.62 (93.5) 0.11 (6.5)
40 2.41 1.74 (72.2) 2.35 (97.5) 0.06 (2.5)
>40 3.09 2.62 (84.7) 3.04 (98.4) 0.05 (1.5)
Total 1.53 1.13 (73.6) 1.44 (93.9) 0.09 (6.1)
Data are presented as %, unless otherwise indicated.
a The incidences of trisomy 21, trisomy 18, and trisomy 13 were comparable among women aged 35 years, 36 years, 37 years, and 38 years (p ¼ 0.133), but began to
signiﬁcantly increase in those aged 39 years and older (p < 0.001).
b The incidences of trisomy 21, trisomy 18, trisomy 13, Turner syndrome, 47,XXX, 47,XXY, 47,XYY, 69,XXY, and 69,XYY were comparable among women aged 35 years,
36 years, 37 years, and 38 years (p ¼ 0. 124), but began to signiﬁcantly increase in those years 39 years and older (p < 0.001).
c Except for the ﬁve common abnormalities in the number of chromosomes, the incidence of other clinically signiﬁcant chromosomal abnormalities (such as partial
chromosomal deletions and unbalanced translocations) did not increase with age (p > 0.05), and their relative incidence of total chromosomal abnormalities showed a
decreasing tendency with age (p < 0.05).
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of AMA women who had undergone prenatal diagnosis. It must be
noted, however, that NIPT has only been available in China since
2012, and given the length of the study period, this may have
inﬂuenced the results.
In cases in which there are no ultrasound abnormalities, less
than two ultrasound soft markers, no genetic history of chro-
mosomal rearrangements, and no nuchal translucency abnor-
malities, rapid molecular diagnostic techniques such as QF-PCR
and FISH can detect approximately 99.9% of CSCAs [7,12,28]. Our
results showed that the ﬁve most common chromosomal ab-
normalities accounted for 93.9% of all CSCAs. If QF-PCR and
FISH miss 6.1% of other CSCAs, these missed diagnoses would
account for 0.09% of all AMA pregnant women seeking prenatal
screening. In other words, a normal QF-PCR or FISH result would
indicate a 99.9% chance of no CSCAs, which is consistent with
other reports [4].
Although CMA can be used to analyze genome copy number,
and is capable of detecting chromosomal abnormalities and copy
number variations (CNVs) [9,16], it is expensive and not always
interpretable. The present study suggested no particular advantage
of CMA in pregnant women older than 35 years.
The present study has certain limitations. Amniocentesis and
karyotype analysis of amniotic ﬂuid were performed at
18e22þ6 weeks of gestation, and AMA was the sole reason for ge-
netic testing. We did not examine ﬁrst trimester testing and
screening methods, so results may be different in a patient popu-
lation with other risk factors for fetal chromosomal anomalies. The
93.9% rate that we found for the ﬁve most common types of
chromosomal anomalies is lower than the rates reported in the
literature [7,13,23]. This may be because the majority of women in
this study did not undergo regular ultrasound screening during the
second trimester before prenatal diagnosis, and some cases may
have shown abnormalities if ultrasound had been performed.Conclusion
Results of this study showed that the rates of fetal chromosomal
abnormalities among AMA women in China are different from
those in other populations and that newer technologies may be
appropriate as alternatives to karyotype analysis. These ﬁndings
may assist in the genetic counseling of AMA pregnant women, and
provide a basis for the selection of prenatal screening and diag-
nostic technologies, and for the rational allocation of resources for
prenatal diagnosis.Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.
Acknowledgments
This work was supported by the National 11th Five-year Plan of
the Science and Technology Support Program (No. 2006BAI05A10)
and the Program for Zhejiang Leading Team of Scientiﬁc and
Technological Innovation, P.R. China (No. 2011R50013-15).
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.tjog.2016.01.002.
References
[1] Heffner LJ. Advanced maternal agedhow old is too old? N Engl J Med
2004;351:1927e9.
[2] ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77:
screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109:
217e27.
[3] Ministry of Health, People's Republic of China. Report on the prevention and
treatment of newborn defects for 2012. Sept.12,2012. Available at: http://
www.gov.cn/gzdt/att/att/site1/20120912/1c6f6506c7f811bacf9301.pdf.
[4] Liao C, Yi CX, Li FT, Li DZ. The prevalence of non-detectable chromosomal ab-
normalities by QF-PCR in amniocentesis for certain referral indications: expe-
rience at a mainland Chinese hospital. Arch Gynecol Obstet 2014;289:75e8.
[5] Bian XM, Guo Q, Qi QW. Current situation and development of prenatal
diagnosis in China. Front Med China 2010;4:271e4.
[6] Wang D, Shi Y, Stewart D, Chang C, Li CY. Factors associated with the utili-
zation and quality of prenatal care in western rural regions of China. Health
Educ 2012;112:4e14.
[7] Ogilvie CM, Lashwood A, Chitty L, Waters JJ, Scriven PN, Flinter F. The future of
prenatal diagnosis: rapid testing or full karyotype? An audit of chromosome
abnormalities and pregnancy outcomes for women referred for Down's syn-
drome testing. BJOG 2005;112:1369e75.
[8] Vialard F, Simoni G, Gomes DM, Abourra A, De Toffol S, Bru F, et al. Prenatal
BACs-on-Beads™: the prospective experience of ﬁve prenatal diagnosis lab-
oratories. Prenat Diagn 2012;32:329e35.
[9] Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. Chromo-
some microarray versus karyotyping for prenatal diagnosis. N Engl J Med
2012;367:2175e84.
[10] Wellesley DG, Lucassen A. Prenatal diagnosis of chromosomal imbalances.
Arch Dis Child Fetal Neonatal Ed 2014;99:F338e41.
[11] Norwitz ER, Levy B. Noninvasive prenatal testing: the future is now. Rev
Obstet Gynecol 2013;6:48e62.
[12] Speevak MD, McGowan-Jordan J, Chun K. The detection of chromosome
anomalies by QF-PCR and residual risks as compared to G-banded analysis.
Prenat Diagn 2011;31:454e8.
[13] Mademont-Soler I, Morales C, Clusellas N, Soler A, Sanchez A. Group of Cy-
togenetics from Hospital Clínic de Barcelona. Prenatal cytogenetic diagnosis in
Spain: analysis and evaluation of the results obtained from amniotic ﬂuid
Y. Zhu et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 379e384384samples during the last decade. Eur J Obstet Gynecol Reprod Biol 2011;157:
156e60.
[14] Qi QW, Jiang YL, Zhou XY, Liu JT, Yin J, Bian XM. Genetic counseling, prenatal
screening and diagnosis of Down syndrome in second trimester in women of
advanced maternal age: a prospective study. Chin Med J (Engl) 2013;126:
2007e10.
[15] American College of Obstetricians and Gynecologists. Practice bulletin. Inva-
sive prenatal testing for aneuploidy. ACOG Pract Bull 88. Obstet Gynecol
2007;110:1459e67.
[16] Lo JO, Shaffer BL, Feist CD, Caughey AB. Chromosomal microarray analysis and
prenatal diagnosis. Obstet Gynecol Surv 2014;69:613e21.
[17] Bornstein E, Lenchner E, Donnenfeld A, Barnhard Y, Seubert D, Divon MY.
Advanced maternal age as a sole indication for genetic amniocentesis; risk-
beneﬁt analysis based on a large database reﬂecting the current common
practice. J Perinat Med 2009;37:99e102.
[18] Resta RG. Changing demographics of advanced maternal age (AMA) and the
impact on the predicted incidence of Down syndrome in the United States:
implications for prenatal screening and genetic counseling. Am J Med Genet A
2005;133:31e6.
[19] Chang YH, Chen PY, Li TY, Yeh CN, Li YS, Chu SY, et al. Discrepancy of cyto-
genetic analysis in Western and eastern Taiwan. Pediatr Neonatol 2013;54:
161e5.
[20] Cogulu O, Ozkinay F, Akin H, Onay H, Karaca E, Durmaz AA, et al. Reasons for
adult referrals for genetic counseling at a genetics center in Izmir, Turkey:
analysis of 8965 cases over an eleven-year period. J Genet Couns 2011;20:
287e93.[21] Tseng JJ, Chou MM, Lo FC, Lai HY, Chen MH, Ho ES. Detection of chromosome
aberrations in the second trimester using genetic amniocentesis: experience
during 1995e2004. Taiwan J Obstet Gynecol 2006;45:39e41.
[22] Danisman N, Kahyaoglu S, Celen S, Kahyaoglu I, Candemir Z, Yesilyurt A, et al.
A retrospective analysis of amniocenteses performed for advanced maternal
age and various other indications in Turkish women. J Matern Fetal Neonatal
Med 2013;26:242e5.
[23] Driscoll DA, Gross S. Clinical practice. Prenatal screening for aneuploidy.
N Engl J Med 2009;360:2556e62.
[24] Forabosco A, Percesepe A, Santucci S. Incidence of non-age-dependent chro-
mosomal abnormalities: a population-based study on 88965 amniocenteses.
Eur J Hum Genet 2009;17:897e903.
[25] Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al.
First-trimester or second-trimester screening, or both, for Down's syndrome.
N Engl J Med 2005;353:2001e11.
[26] Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal
aneuploidies by massively parallel sequencing in a prospective Chinese
population. Prenat Diagn 2013;33:700e6.
[27] Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of cell-
free DNA in maternal blood in screening for aneuploidies: meta-analysis.
Fetal Diagn Ther 2014;35:156e73.
[28] Hills A, Donaghue C, Waters J, Waters K, Sullivan C, Kulkarni A, et al. QF-PCR as
a stand-alone test for prenatal samples: the ﬁrst 2 years' experience in the
London region. Prenat Diagn 2010;30:509e17.
